Preclinical evaluation of the breast cancer cell-binding peptide, p160

Clinical Cancer Research

Volumn 11, Issue 18, 2005, Pages 6705-6712

  Askoxylakis, Vasileios ^a,b   Zitzmann, Sabine ^a,b   Mier, Walter ^b   Graham, Keith ^b   Krämer, Susanne ^b   Von Wegner, Frederic ^b   Fink, Rainer H A ^b   Schwab, Manfred ^a   Eisenhut, Michael ^a   Haberkorn, Uwe ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BINDING PROTEIN; FLUORESCEIN ISOTHIOCYANATE; IODINE 125; IODINE 131; PROTEIN P160;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DISTRIBUTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; MOLECULAR STABILITY; MOUSE; NONHUMAN; NUDE MOUSE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; NEOPLASM TRANSPLANTATION; OCTREOTIDE; OLIGOPEPTIDES; RADIOLIGAND ASSAY; TIME FACTORS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 25144516609     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0432     Document Type: Article

References (33)

1. Rakhmilevich AL, Hooper AT, Hicklin DJ, Sondel PM. Treatment of experimental breast cancer using interleukin-12 gene therapy combined with antivascular endothelial growth factor receptor-2 antibody. Mol Cancer Ther 2004;3:969-76.
2. Toi M, Takada M, Bando H, et al. Current status of antibody therapy for breast cancer. Breast Cancer 2004;11:10-4.
3. Takahashi M, Inoue K, Goto R, et al. Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report. Breast Cancer 2003;10:170-4.
4. Colcher D, Goel A, Pavlinkova G, Beresford G, Booth B, Batra SK. Effects of genetic engineering on the pharmacokinetics of antibodies. Q J Nucl Med 1999;43:132-9.
5. Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 2002;62:5139-43.
6. 3-integrin expression. J Nucl Med 2004;45:1776-83.
7. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5.
8. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722-7.
9. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled α(v)β(3) integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-51.
10. Landon LA, Deutscher SL. Combinatorial discovery of tumor targeting peptides using phage display. J Cell Biochem 2003;90:509-17.
11. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380:364-6
12. Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol 2000;301:1149-61.
13. Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med 1996;2:299-305.
14. Zhang J, Spring H, Schwab M. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett 2001;171:153-64.
15. Wellings DA, Atherton E. Standard Fmoc protocols. Methods Enzymol 1997;289:44-67.
16. Crim JW, Garczynski SF, Brown MR. Approaches to radioiodination of insect neuropeptides. Peptides 2002;23:2045-51.
17. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-56.
18. Okarvi SM. Synthesis, radiolabeling and in vitro and in vivo characterization of a technetium-99m-labeled α-M2 peptide as a tumor imaging agent. J Pept Res 2004;63:460-8.
19. Garcia-Garayoa E, Allemann-Tannahill L, Blauenstein P, et al. In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors. Nucl Med Biol 2001;28:75-84.
20. Kuhnast B, Bodenstein C, Haubner R, et al. Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. Nucl Med Biol 2004;31:337-44.
21. Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412-7.
22. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
23. Rait AS, Pirollo KF, Xiang L, Ulick D, Chang EH. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med 2002;8:475-86.
24. Jhaveri MS, Rait AS, Chung KN, Trepel JB, Chang EH. Antisense oligonucleotides targeted to the human α folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther 2004;3:1505-12.
25. Jain RK. Delivery of molecular and cellular medicine to solid tumors. J Control Release 1998;53:49-67.
26. Lee SH, Lee S, Youn YS, et al. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem 2005;16:377-82.
27. Ichikawa K, Hikita T, Maeda N, et al. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim Biophys Acta 2005;1669:69-74.
28. 1 integrins. J Biol Chem 1994;269:20233-8.
29. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715.
30. v Integrins mediate adhesion and migration of breast carcinoma cell lines. Clin Exp Metastasis 1998;16: 50-61.
31. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
32. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-36.
33. van Hagen PM, Breeman WA, Bernard HF, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 2000;90:186-98.